Advertisement

Topics

COMBINE (Acamprosate/Naltrexone)

2014-07-23 21:56:23 | BioPortfolio

Summary

Combine is a multicenter, randomized clinical trial that will evaluate combinations of three interventions for treating alcohol dependence. The goal is to determine whether improvement in treatment outcomes can be achieved by various combinations of drug and behavioral interventions. Two of the interventions will consist of pharmacological treatment with naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including AA. All three interventions will include a component supporting compliance to medications and reduction in drinking.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Conditions

Alcoholism

Intervention

naltrexone (Revia), acamprosate (Campral)

Location

Substance Abuse Treatment Unit, Yale University
New Haven
Connecticut
United States
06511

Status

Completed

Source

University of North Carolina, Chapel Hill

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:56:23-0400

Clinical Trials [269 Associated Clinical Trials listed on BioPortfolio]

Naltrexone Treatment for Alcoholism

This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of thei...

Individually Adapted Therapy of Alcoholism

The primary objective is to directly compare the efficacy of acamprosate, naltrexone and placebo for relapse prevention in alcoholics.

Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic

This is a study of a medication, Campral (acamprosate), which is an FDA approved medication for alcohol problems. We will be examining whether acamprosate (Campral) compared to a sugar pi...

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence. This st...

Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)

The purpose of this study is to determine the effectiveness of naltrexone (Revia) in reducing drinking and smoking in patients with both nicotine and alcohol dependence. Individuals will ...

PubMed Articles [203 Associated PubMed Articles listed on BioPortfolio]

Insomnia in Alcohol-Dependent Patients: Prevalence, Risk Factors and Acamprosate Effect: An Individual Patient Data Meta-Analysis.

The prevalence of insomnia ranges from 36% to 91% in alcohol-dependent patients and may persist after alcohol withdrawal. Acamprosate has been shown to decrease insomnia in abstinent patients. Based o...

Dreadd to the core. Commentary on Purohit et al. (2018): Pharmacogenetic manipulation of the nucleus accumbens alters binge-like alcohol drinking in mice.

Alcohol use disorders (AUDs) are a devastating class of addictive disorders that incur a tremendous societal and economic burden. AUDs cost an estimated annual $235 billion in the United States (Rehm ...

Calcium chloride mimics the effects of acamprosate on cognitive deficits in chronic alcohol-exposed mice.

Acamprosate (calcium-bis N-acetylhomotaurinate) is the leading medication approved for the maintenance of abstinence, shown to reduce craving and relapse in animal models and human alcoholics. Acampro...

Co-administration of low-dose naltrexone and bupropion reduces alcohol drinking in alcohol-preferring (P) rats.

This study examined whether combining naltrexone (NTX) with bupropion (BUP) is more effective in reducing alcohol drinking in alcohol-preferring (P) rats with a genetic predisposition toward high volu...

DRUG-DRUG INTERACTIONS IN THE TREATMENT FOR ALCOHOL USE DISORDERS: A COMPREHENSIVE REVIEW.

Drug interactions are one of the most common causes of side effects in polypharmacy. Alcoholics are a category of patients at high risk of pharmacological interactions, due to the presence of comorbid...

Medical and Biotech [MESH] Definitions

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)

Component of the NATIONAL INSTITUTES OF HEALTH. It conducts research focused on improving the treatment and prevention of alcoholism and alcohol-related problems to reduce the health, social, and economic consequences of this disease. NIAAA, NIMH, and NIDA were created as coequal institutes within the Alcohol, Drug Abuse and Mental Health Administration in 1974. It was established within the NATIONAL INSTITUTES OF HEALTH in 1992.

A plant genus of the family FABACEAE a common weed of the southeast US. There has been folk use for alcoholism and liver protection. It contains puerarin, kakkalide, daidzein (isoflavonoids), and kudzusaponins (oleanene-type triterpene glycosides).

A mental disorder associated with chronic ethanol abuse (ALCOHOLISM) and nutritional deficiencies characterized by short term memory loss, confabulations, and disturbances of attention. (Adams et al., Principles of Neurology, 6th ed, p1139)

More From BioPortfolio on "COMBINE (Acamprosate/Naltrexone)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Searches Linking to this Trial